viltolarsen   Click here for help

GtoPdb Ligand ID: 11430

Synonyms: NCNP-01 | NS-065 | Viltepso®
Approved drug
viltolarsen is an approved drug (FDA (2020))
Compound class: Synthetic organic
Comment: Viltolarsen is an antisense phosphorodiamidate morpholino oligomer (PMO) class nucleotide drug. Its abbreviated chemical/nucleotide structure is all-P-ambo-[2',3'-azanediyl-P,2',3'-trideoxy-P-(dimethylamino)-2',3'-seco](2'-N→5')(CCTCCGGTTCTGAAGGTGTTC). Viltolarsen restores the reading frame of certain dystrophin gene mutations and promotes synthesis of a shorter but functional dystrophin protein.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 141
Hydrogen bond donors 29
Rotatable bonds 122
Topological polar surface area 2504.15
Molecular weight 6921.36
XLogP -21.82
No. Lipinski's rules broken 3
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@@H]1CN(C[C@@H](O1)n1ccc(nc1=O)N)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@@H]1CNC[C@@H](O1)n1ccc(nc1=O)N)n1cc(C)c(=O)[nH]c1=O)n1cc(C)c(=O)[nH]c1=O)n1cnc2c1nc(N)[nH]c2=O)n1cc(C)c(=O)[nH]c1=O)n1cnc2c1nc(N)[nH]c2=O)n1cnc2c1nc(N)[nH]c2=O)n1cnc2c1ncnc2N)n1cnc2c1ncnc2N)n1cnc2c1nc(N)[nH]c2=O)n1cc(C)c(=O)[nH]c1=O)n1cc(C)c(=O)[nH]c1=O)n1cc(C)c(=O)[nH]c1=O)n1cnc2c1nc(N)[nH]c2=O)n1cnc2c1nc(N)[nH]c2=O)n1ccc(nc1=O)N)n1ccc(nc1=O)N)n1cc(C)c(=O)[nH]c1=O)n1ccc(nc1=O)N)n1ccc(nc1=O)N
Isomeric SMILES OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@@H]1CN(C[C@@H](O1)n1ccc(nc1=O)N)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@H]1O[C@H](CN(C1)P(=O)(N(C)C)OC[C@@H]1CNC[C@@H](O1)n1ccc(nc1=O)N)n1cc(C)c(=O)[nH]c1=O)n1cc(C)c(=O)[nH]c1=O)n1cnc2c1nc(N)[nH]c2=O)n1cc(C)c(=O)[nH]c1=O)n1cnc2c1nc(N)[nH]c2=O)n1cnc2c1nc(N)[nH]c2=O)n1cnc2c1ncnc2N)n1cnc2c1ncnc2N)n1cnc2c1nc(N)[nH]c2=O)n1cc(C)c(=O)[nH]c1=O)n1cc(C)c(=O)[nH]c1=O)n1cc(C)c(=O)[nH]c1=O)n1cnc2c1nc(N)[nH]c2=O)n1cnc2c1nc(N)[nH]c2=O)n1ccc(nc1=O)N)n1ccc(nc1=O)N)n1cc(C)c(=O)[nH]c1=O)n1ccc(nc1=O)N)n1ccc(nc1=O)N
InChI Key ZVXLKCOOOKREJD-OERAVCCFSA-N
References
1. Roshmi RR, Yokota T. (2019)
Viltolarsen for the treatment of Duchenne muscular dystrophy.
Drugs Today (Barc), 55 (10): 627-639. [PMID:31720560]